Logo

Novartis Terminates its Agreement with Akcea for AKCEA-APOCIII-LRx

Share this

Novartis Terminates its Agreement with Akcea for AKCEA-APOCIII-LRx

Shots:

  • Akcea retains exclusive rights to develop and commercialize AKCEA-APOCIII-LRx following Novartis’ decision for not exercising the option
  • In 2017- Novartis signed an option agreement with Akcea for two antisense therapies AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular disease. In Feb 2019 Novartis exercised its option for AKCEA-APO(a)-LRx due to strategic portfolio reason - further decided not to exercise option for second therapy i.e. AKCEA-APOCIII-LRx
  • AKCEA-APOCIII-LRx is ligand conjugated antisense (LICA) drug co-developed by Akcea and Ionis using ionis’ advanced LIgand Conjugated Antisense (LICA) technology platform and is currently in P-II for patients with hypertriglyceridemia and CVD with expected results in H1’20

Click here to read full press release/ article | Ref: GlobeNewswire | Image: Signbox


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions